The safety of studies with intravenous Δ 9- tetrahydrocannabinol in humans, with case histories

Psychopharmacology

Volumn 219, Issue 3, 2012, Pages 885-896

  Carbuto, Michelle ^a,c   Sewell, R Andrew ^a,c   Williams, Ashley ^a,c   Forselius Bielen, Kim ^a,b,c   Braley, Gabriel ^a,c   Elander, Jacqueline ^a,c   Pittman, Brian ^b,c   Schnakenberg, Ashley ^a,c   Bhakta, Savita ^a,c   Perry, Edward ^a,b,c   Ranganathan, Mohini ^a,b,c   D'Souza, Deepak Cyril ^a,b,c  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b Abraham Ribicoff Research Facilities   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abuse; Cannabinoids; Schizophrenia; THC

Indexed keywords

DRONABINOL; HALOPERIDOL; IOMAZENIL; NALTREXONE; PHYSOSTIGMINE; PLACEBO; TOLCAPONE;

ADULT; ANXIETY DISORDER; ARTICLE; CANNABIS ADDICTION; CHEST TIGHTNESS; CLINICAL TRIAL; DECISION MAKING; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; FEMALE; FOLLOW UP; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; NAUSEA; PARANOIA; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; TACHYCARDIA; TACHYPNEA; THORAX PAIN; TREATMENT DURATION; VERTIGO; VOMITING;

ADOLESCENT; ADULT; ANXIETY; DRUG TOXICITY; FEMALE; HUMANS; MALE; MARIJUANA SMOKING; MIDDLE AGED; PARANOID DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAHYDROCANNABINOL; TIME FACTORS; YOUNG ADULT;

EID: 84856680138     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2417-y     Document Type: Article

References (58)

1. Adlaf EM (2003) Drug use among Ontario students 1977-2003: findings from OSDUS. Center for Addiction and Mental Health, Toronto
2. S Agurell M Halldin JE Lindgren A Ohlsson M Widman H Gillespie L Hollister 1986 Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man Pharmacol Rev 38 21 43 3012605 1:CAS:528:DyaL28XktlCqs70%3D (Pubitemid 16077324)
3. V Alfonso Moreno F Ojesa E Moreno-Osset 2006 Cannabinoid hyperemesis Gastroenterol Hepatol 29 434 435 16938265 10.1157/13091459 (Pubitemid 44386364)
4. JL Azorlosa MK Greenwald ML Stitzer 1995 Marijuana smoking: effects of varying puff volume and breathhold duration J Pharmacol Exp Ther 272 560 569 7853169 1:CAS:528:DyaK2MXjs1OhsLs%3D
5. JA Bachman NL Benowitz RI Herning RT Jones 1979 Dissociation of autonomic and cognitive effects of THC in man Psychopharmacology (Berl) 61 171 175 10.1007/BF00426733 1:CAS:528:DyaE1MXktVSns7w%3D (Pubitemid 9235852)
6. Barkus E, Morrison PD, Vuletic D, Dickson J, Ell PJ, Pilowsky LS, Brenneisen R, Holt DW, Powell J, Kapur S, Murray RM (2010) Does intravenous {triangleup}9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol (in press)
7. Beaumont H, Jensen J, Carlsson A, Ruth M, Lehmann A, Boeckxstaens G (2009) Effect of delta-9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol 156:153-62
8. K ben Amar M Yondorf JJ Meissler EB Geller RJ Tallarida TK Eisenstein MW Adler 2007 A novel role of cannabinoids: implication in the fever induced by bacterial lipopolysaccharide J Pharmacol Exp Ther 320 1127 1133 10.1124/jpet.106.113159 1:CAS:528:DC%2BD2sXis1Wgtb0%3D (Pubitemid 46294067)
9. S Bhattacharyya PD Morrison P Fusar-Poli R Martin-Santos S Borgwardt T Winton-Brown C Nosarti OC CM M Seal P Allen MA Mehta JM Stone N Tunstall V Giampietro S Kapur RM Murray AW Zuardi JA Crippa Z Atakan PK McGuire 2010 Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology Neuropsychopharmacology 35 764 774 19924114 10.1038/npp.2009.184 1:CAS:528:DC%2BC3cXhtlCrur0%3D
10. MG Bossong BN van Berckel R Boellaard L Zuurman RC Schuit AD Windhorst JM van Gerven NF Ramsey AA Lammertsma RS Kahn 2008 Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum Neuropsychopharmacology 34 3 759 766 18754005 10.1038/npp.2008.138
11. V Budhraja 2009 Confirming the diagnosis of cannabinoid hyperemesis Mayo Clin Proc 84 483 19411446 author reply 483
12. KM Carpenter D McDowell DJ Brooks WY Cheng FR Levin 2009 A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence Am J Addict 18 53 64 19219666 10.1080/10550490802408936
13. KM Carroll BJ Rounsaville C Nich LT Gordon PW Wirtz F Gawin 1994 One-year follow-up of psychotherapy and pharmacotherapy for cocaine dependence. Delayed emergence of psychotherapy effects Arch Gen Psychiatry 51 989 997 7979888 10.1001/archpsyc.1994.03950120061010 1:STN:280:DyaK2M%2FntVKktQ%3D%3D (Pubitemid 24371869)
14. YH Chang DM Windish 2009 Cannabinoid hyperemesis relieved by compulsive bathing Mayo Clin Proc 84 76 78 19121257 10.4065/84.1.76
15. NL Cluny RJ Naylor BA Whittle FA Javid 2008 The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus Basic Clin Pharmacol Toxicol 103 150 156 18816298 10.1111/j.1742-7843.2008.00253.x 1:CAS:528:DC%2BD1cXpslWhu7o%3D (Pubitemid 352022723)
16. J Cotter 2009 Efficacy of crude marijuana and synthetic delta-9-tetrahydrocannabinol as treatment for chemotherapy-induced nausea and vomiting: a systematic literature review Oncol Nurs Forum 36 345 352 19596652 10.1188/09.ONF.345-352
17. DC D'Souza WM Abi-Saab S Madonick K Forselius-Bielen A Doersch G Braley R Gueorguieva TB Cooper JH Krystal 2005 Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction Biol Psychiatry 57 594 608 15780846 10.1016/j.biopsych.2004.12.006 (Pubitemid 40409699)
18. DC D'Souza G Braley R Blaise M Vendetti S Oliver B Pittman M Ranganathan S Bhakta Z Zimolo T Cooper E Perry 2008 Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of delta-9-tetrahydrocannabinol in humans Psychopharmacology (Berl) 198 587 603 10.1007/s00213-007-1042-2
19. DC D'Souza RB Gil S Madonick EB Perry K Forselius-Bielen G Braley L Donahue T Tellioglu Z Zimolo R Gueorguieva JH Krystal 2006 Enhanced sensitivity to the euphoric effects of alcohol in schizophrenia Neuropsychopharmacology 31 2767 2775 16985503 10.1038/sj.npp.1301207 (Pubitemid 44764173)
20. DC D'Souza E Perry L MacDougall Y Ammerman T Cooper YT Wu G Braley R Gueorguieva JH Krystal 2004 The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis Neuropsychopharmacology 29 1558 1572 15173844 10.1038/sj.npp.1300496 (Pubitemid 38982249)
21. DC D'Souza M Ranganathan G Braley R Gueorguieva Z Zimolo T Cooper E Perry J Krystal 2008 Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis Neuropsychopharmacology 33 2505 2516 18185500 10.1038/sj.npp.1301643
22. D D'Souza R Berman J Krystal D Charney 1999 Symptom provocation studies in psychiatric disorders: scientific value, risks, and future Hum Psychopharmacol 26 77 80
23. MW Donnino MN Cocchi J Miller J Fisher 2009 Cannabinoid hyperemesis: a case series J Emerg Med 40 e63 e66 19765941 10.1016/j.jemermed.2009.07.033
24. F Grotenhermen 2003 Pharmacokinetics and pharmacodynamics of cannabinoids Clin Pharmacokinet 42 327 360 12648025 10.2165/00003088-200342040-00003 1:CAS:528:DC%2BD3sXjsFWis7g%3D (Pubitemid 36433875)
25. JR Johnson M Burnell-Nugent D Lossignol ED Ganae-Motan R Potts MT Fallon 2010 Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain J Pain Symptom Manage 39 167 179 19896326 10.1016/j.jpainsymman.2009.06.008
26. Keeley PW (2009) Nausea and vomiting in people with cancer and other chronic diseases. Clin Evid (Online) 01:2406
27. L Kohn F Kittel D Piette 2004 Peer, family integration and other determinants of cannabis use among teenagers Int J Adolesc Med Health 16 359 370 15712973 10.1515/IJAMH.2004.16.4.359 (Pubitemid 40227593)
28. Krystal JH, Abi-Dargham A, Laruelle M, Moghaddam B (1999) Pharmacological model psychoses. Oxford University Press, New York, NY
29. JH Krystal W Abi-Saab E Perry DC D'Souza N Liu R Gueorguieva L McDougall T Hunsberger A Belger L Levine A Breier 2005 Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects Psychopharmacology (Berl) 179 303 309 10.1007/s00213-004-1982-8 1:CAS:528:DC%2BD2MXjtV2it70%3D (Pubitemid 40576718)
30. JH Krystal LP Karper A Bennett DC D'Souza A Abi-Dargham K Morrissey D Abi-Saab JD Bremner MB Bowers Jr RF Suckow P Stetson GR Heninger DS Charney 1998 Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans Psychopharmacology (Berl) 135 213 229 10.1007/s002130050503 1:CAS:528:DyaK1cXhtFCktLs%3D (Pubitemid 28055456)
31. JH Krystal S Madonick E Perry R Gueorguieva L Brush Y Wray A Belger DC D'Souza 2006 Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism Neuropsychopharmacology 31 1793 1800 16395307 10.1038/sj.npp.1300994 1:CAS:528:DC%2BD28XmvFCnur4%3D (Pubitemid 44106711)
32. JH Krystal EB Perry Jr R Gueorguieva A Belger SH Madonick A Abi-Dargham TB Cooper L Macdougall W Abi-Saab DC D'Souza 2005 Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function Arch Gen Psychiatry 62 985 994 16143730 10.1001/archpsyc.62.9.985 1:CAS:528: DC%2BD2MXhtVGgtrvK (Pubitemid 41248378)
33. JH Krystal IL Petrakis E Webb NL Cooney LP Karper S Namanworth P Stetson LA Trevisan DS Charney 1998 Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics Arch Gen Psychiatry 55 354 360 9554431 10.1001/archpsyc.55.4.354 1:CAS:528:DyaK1cXis1Wrs7c%3D (Pubitemid 28173625)
34. L Lemberger J Axelrod IJ Kopin 1971 Metabolism and disposition of delta-9-tetrahydrocannabinol in man Pharmacol Rev 23 371 380 4943951 1:CAS:528:DyaE38XpsVelsQ%3D%3D
35. L Lemberger R Martz B Rodda R Forney H Rowe 1973 Comparative pharmacology of delta 9-tetrahydrocannabinol and its metabolite, 11-OH-delta 9-tetrahydrocannabinol J Clin Invest 52 2411 2417 4729039 10.1172/JCI107431 1:CAS:528:DyaE2cXhtVGisw%3D%3D
36. JE Lindgren A Ohlsson S Agurell L Hollister H Gillespie 1981 Clinical effects and plasma levels of delta-9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis Psychopharmacology (Berl) 74 208 212 10.1007/BF00427095 1:CAS:528:DyaL3MXlt1Khs78%3D (Pubitemid 11034573)
37. LA Malit RE Johnstone DI Bourke RA Kulp V Klein TC Smith 1975 Intravenous delta9-Tetrahydrocannabinol: effects of ventilatory control and cardiovascular dynamics Anesthesiology 42 666 673 1130738 10.1097/00000542-197506000-00008 1:CAS:528:DyaE2MXltVymuro%3D
38. GW Martin DA Wilkinson BM Kapur 1988 Validation of self-reported cannabis use by urine analysis Addict Behav 13 147 150 2835893 10.1016/0306-4603(88) 90004-4 1:STN:280:DyaL1c3itVWjsw%3D%3D
39. PD Morrison J Nottage JM Stone S Bhattacharyya N Tunstall R Brenneisen D Holt A Wilson A Sumich P McGuire RM Murray BM Kapur DH ffytche 2011 Disruption of frontal theta coherence by D9-tetrahydrocannabinol is associated with positive psychotic symptoms Neuropsychopharmacology 36 827 836 21150914 10.1038/npp.2010.222 1:CAS:528:DC%2BC3MXhs1ylurc%3D
40. PD Morrison JM Stone 2011 Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation Hum Psychopharmacol 26 77 80 10.1002/hup.1166 1:CAS:528:DC%2BC3MXlsFKlurs%3D
41. PD Morrison V Zois DA McKeown TD Lee DW Holt JF Powell S Kapur RM Murray 2009 The acute effects of synthetic intravenous delta-9-tetrahydrocannabinol on psychosis, mood and cognitive functioning Psychol Med 39 1607 1616 19335936 10.1017/S0033291709005522 1:STN:280:DC%2BD1MnhtFKksA%3D%3D
42. M Naef S Russmann S Petersen-Felix R Brenneisen 2004 Development and pharmacokinetic characterization of pulmonal and intravenous delta-9-tetrahydrocannabinol (THC) in humans J Pharm Sci 93 1176 1184 15067694 10.1002/jps.20037 1:CAS:528:DC%2BD2cXjsFKisbw%3D (Pubitemid 38529691)
43. A Ohlsson JE Lindgren A Wahlen S Agurell LE Hollister HK Gillespie 1980 Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking Clin Pharmacol Ther 28 409 416 6250760 10.1038/clpt.1980.181 1:CAS:528:DyaL3cXlvFOnu70%3D (Pubitemid 10007024)
44. M Perez-Reyes MC Timmons MA Lipton KH Davis ME Wall 1972 Intravenous injection in man of delta-9-tetrahydrocannabinol and 11-OH-delta-9- tetrahydrocannabinol Science 177 633 635 4558903 10.1126/science.177.4049.633 1:CAS:528:DyaE38XltlGhu74%3D
45. EB Perry Jr JA Cramer HS Cho IL Petrakis LP Karper A Genovese E O'Donnell JH Krystal DC D'Souza 2007 Psychiatric safety of ketamine in psychopharmacology research Psychopharmacology (Berl) 192 253 260 10.1007/s00213-007-0706-2 1:CAS:528:DC%2BD2sXkslWgsb8%3D (Pubitemid 46669207)
46. RG Pertwee 2006 The pharmacology of cannabinoid receptors and their ligands: an overview Int J Obes (Lond) 30 Suppl 1 S13 S18 10.1038/sj.ijo.0803272 1:CAS:528:DC%2BD28XivFSmurw%3D
47. RG Pertwee 2008 The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta 9-tetrahydrocannabivarin Br J Pharmacol 153 199 215 17828291 10.1038/sj.bjp.0707442 1:CAS:528:DC%2BD1cXovFCkuw%3D%3D
48. D Raft J Gregg J Ghia L Harris 1977 Effects of intravenous tetrahydrocannabinol on experimental and surgical pain. Psychological correlates of the analgesic response Clin Pharmacol Ther 21 26 33 832447 1:STN:280:DyaE2s%2FptVWgtQ%3D%3D (Pubitemid 8024156)
49. P Rosenzweig S Brohier A Zipfel 1993 The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies Clin Pharmacol Ther 54 578 583 8222500 10.1038/clpt.1993.190 1:STN:280:DyaK2c%2Fjslyiuw%3D%3D (Pubitemid 23349095)
50. D Ryan AJ Drysdale RG Pertwee B Platt 2006 Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia Neurosci Lett 408 236 241 16997463 10.1016/j.neulet.2006.09.008 1:CAS:528:DC%2BD28XhtVygtrnN (Pubitemid 44528872)
51. RA Sewell PD Skosnik I Garcia-Sosa M Ranganathan DC D'Souza 2010 Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia Rev Bras Psiquiatr 32 Suppl 1 S15 S30 20512267
52. E Singh W Coyle 2008 Cannabinoid hyperemesis Am J Gastroenterol 103 1048 1049 18397435 10.1111/j.1572-0241.2007.01772-11.x (Pubitemid 351501109)
53. SP Sontineni S Chaudhary V Sontineni SJ Lanspa 2009 Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse World J Gastroenterol 15 1264 1266 19291829 10.3748/wjg.15.1264
54. PR Stokes MA Mehta HV Curran G Breen PM Grasby 2009 Can recreational doses of THC produce significant dopamine release in the human striatum? Neuroimage 48 186 190 19539765 10.1016/j.neuroimage.2009.06.029
55. ND Volkow H Gillespie N Mullani L Tancredi C Grant M Ivanovic L Hollister 1991 Cerebellar metabolic activation by delta-9-tetrahydro-cannabinol in human brain: a study with positron emission tomography and 18F-2-fluoro-2-deoxyglucose Psychiatry Res 40 69 78 1658842 10.1016/0925-4927(91)90030-T 1:CAS:528:DyaK3MXmslSnt7g%3D
56. ND Volkow H Gillespie N Mullani L Tancredi C Grant A Valentine L Hollister 1996 Brain glucose metabolism in chronic marijuana users at baseline and during marijuana intoxication Psychiatry Res 67 29 38 8797240 10.1016/0925-4927(96)02817-X 1:CAS:528:DyaK28XksVOhsrY%3D (Pubitemid 26000713)
57. ME Wall BM Sadler D Brine H Taylor M Perez-Reyes 1983 Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women Clin Pharmacol Ther 34 352 363 6309462 10.1038/clpt.1983.179 1:CAS:528: DyaL3sXlvVOjsbg%3D (Pubitemid 13006304)
58. D Wallace AL Martin B Park 2007 Cannabinoid hyperemesis: marijuana puts patients in hot water Australas Psychiatry 15 156 158 17464661 10.1080/10398560701196778 (Pubitemid 46705812)